Good ideas and conversation. No ads, no tracking. Login or Take a Tour!
This looks like a potentially good molecule. But, I honestly think that he is over-selling their approach. He didn't mention if they filed a patent on the molecule. I work in cancer research, and people publicly disclose this type of information often, especially after they filed a patent. If they are going to clinical trials, I am almost certain they have. There's not a huge risk for them to share this info, and it's not uncommon. People share reagents all the time too. Actually, if you use public funding, you are supposed to make reagents available.
I'm all for openness. But, this sounded like a number of talks I've been to, but with an angle that is a bit exaggerated. That said, it looks like it could be good stuff. I hope it pans out.
–
Someone needs to figure out how we can share data in increments that aren't journal worthy, and still accumulate credit for it that translates into funding. It's funny, because what constitutes a paper is a 'full story' which means a lot of exploratory work goes unpublished.
Maybe a journal of experimental results?